JP2020514290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514290A5 JP2020514290A5 JP2019536228A JP2019536228A JP2020514290A5 JP 2020514290 A5 JP2020514290 A5 JP 2020514290A5 JP 2019536228 A JP2019536228 A JP 2019536228A JP 2019536228 A JP2019536228 A JP 2019536228A JP 2020514290 A5 JP2020514290 A5 JP 2020514290A5
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- polypeptide
- preparation
- cancer
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443698P | 2017-01-07 | 2017-01-07 | |
| US62/443,698 | 2017-01-07 | ||
| US201762581978P | 2017-11-06 | 2017-11-06 | |
| US62/581,978 | 2017-11-06 | ||
| PCT/US2018/012604 WO2018129331A1 (en) | 2017-01-07 | 2018-01-05 | Dosing regimens and dosage forms for targeted tgf-b inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514290A JP2020514290A (ja) | 2020-05-21 |
| JP2020514290A5 true JP2020514290A5 (enExample) | 2021-02-18 |
Family
ID=62791283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536228A Pending JP2020514290A (ja) | 2017-01-07 | 2018-01-05 | 標的ｔｇｆ−β阻害のための投薬計画及び投薬形態 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190330375A1 (enExample) |
| EP (1) | EP3565599A4 (enExample) |
| JP (1) | JP2020514290A (enExample) |
| KR (1) | KR20190102059A (enExample) |
| CN (1) | CN110198738A (enExample) |
| AU (1) | AU2018205233A1 (enExample) |
| BR (1) | BR112019013924A2 (enExample) |
| CA (1) | CA3048646A1 (enExample) |
| CL (1) | CL2019001871A1 (enExample) |
| IL (1) | IL267856A (enExample) |
| MX (1) | MX2019008001A (enExample) |
| PH (1) | PH12019501574A1 (enExample) |
| RU (1) | RU2019124875A (enExample) |
| SG (1) | SG11201906157YA (enExample) |
| WO (1) | WO2018129331A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| JP2021528399A (ja) * | 2018-06-22 | 2021-10-21 | メルク パテント ゲーエムベーハー | 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画 |
| JP2021529777A (ja) * | 2018-07-02 | 2021-11-04 | メルク パテント ゲーエムベーハー | 進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法 |
| CN112672753B (zh) | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| CA3118415A1 (en) * | 2018-11-09 | 2020-05-14 | Jiangsu Hengrui Medicine Co., Ltd. | Tgf-.beta. receptor fusion protein pharmaceutical composition and use thereof |
| SG11202108099WA (en) | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
| KR102815892B1 (ko) | 2019-06-10 | 2025-06-04 | 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 | PDL1 및 TGFβ에 대한 2기능성 융합 단백질 및 이의 용도 |
| CN112574314A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 一种融合蛋白及其应用 |
| WO2021081321A1 (en) * | 2019-10-24 | 2021-04-29 | Amgen Inc. | Systems and approaches for drug delivery |
| US20230044248A1 (en) * | 2019-11-01 | 2023-02-09 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| US20230340122A1 (en) * | 2019-11-05 | 2023-10-26 | Glaxosmithkline Intellectual Property (No. 4) Ltd. | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| US12527839B2 (en) | 2019-11-05 | 2026-01-20 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| CA3158047A1 (en) * | 2019-12-11 | 2021-06-17 | Yunying CHEN | Bi-functional antibody against pd-l1 and tgf? |
| WO2021123432A1 (en) * | 2019-12-20 | 2021-06-24 | Ares Trading S.A. | Igg:tgfbetarii fusion protein composition |
| CN111118064B (zh) * | 2019-12-24 | 2022-10-25 | 华南理工大学 | 一种精子生成障碍动物模型及其制备方法与应用 |
| CA3167427A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgfb inhibitors and use thereof |
| CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| CN115135675A (zh) * | 2020-02-18 | 2022-09-30 | 南京金斯瑞生物科技有限公司 | 融合蛋白及其用途 |
| CN115175942B (zh) * | 2020-02-25 | 2025-05-30 | 上海药明生物技术有限公司 | 一种双功能融合蛋白及其用途 |
| US12194094B2 (en) | 2020-07-10 | 2025-01-14 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| CN116323657B (zh) * | 2020-09-24 | 2023-12-08 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| EP4306131A4 (en) | 2021-03-08 | 2025-06-18 | Nanjing GenScript Biotech Co., Ltd. | ANTIBODY DELIVERY USING A DUAL VIRAL VECTOR SYSTEM |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| EP4351640A1 (en) * | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
| MX2024006018A (es) * | 2021-11-19 | 2024-07-29 | Merus Nv | Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii. |
| EP4676954A1 (en) | 2023-03-07 | 2026-01-14 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785682A (en) * | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
| US8993524B2 (en) * | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20130110045A1 (en) * | 2011-10-31 | 2013-05-02 | Ming-Yuan Wu | Single use intravenous therapy administering device with needle safety covers |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| HRP20210977T1 (hr) * | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| AU2015380397B2 (en) * | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| ES2820768T3 (es) * | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1 |
| DK3294770T4 (da) * | 2015-05-12 | 2024-05-21 | Hoffmann La Roche | Terapeutiske og diagnostiske fremgangsmåder til cancer |
-
2018
- 2018-01-05 CN CN201880006085.0A patent/CN110198738A/zh active Pending
- 2018-01-05 AU AU2018205233A patent/AU2018205233A1/en not_active Abandoned
- 2018-01-05 KR KR1020197022795A patent/KR20190102059A/ko not_active Ceased
- 2018-01-05 EP EP18736497.1A patent/EP3565599A4/en active Pending
- 2018-01-05 RU RU2019124875A patent/RU2019124875A/ru unknown
- 2018-01-05 CA CA3048646A patent/CA3048646A1/en active Pending
- 2018-01-05 JP JP2019536228A patent/JP2020514290A/ja active Pending
- 2018-01-05 SG SG11201906157YA patent/SG11201906157YA/en unknown
- 2018-01-05 WO PCT/US2018/012604 patent/WO2018129331A1/en not_active Ceased
- 2018-01-05 MX MX2019008001A patent/MX2019008001A/es unknown
- 2018-01-05 BR BR112019013924-9A patent/BR112019013924A2/pt not_active Application Discontinuation
-
2019
- 2019-07-02 US US16/460,792 patent/US20190330375A1/en not_active Abandoned
- 2019-07-03 PH PH12019501574A patent/PH12019501574A1/en unknown
- 2019-07-04 IL IL267856A patent/IL267856A/en unknown
- 2019-07-05 CL CL2019001871A patent/CL2019001871A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bianco et al. | Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide | |
| Singh et al. | Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | |
| Molloy et al. | Preclinical characterization of HPN536, a trispecific, T-cell–activating protein construct for the treatment of mesothelin-expressing solid tumors | |
| FI3833386T3 (fi) | Monispesifisiä sitoutuvia proteiineja, jotka sitovat her2:ta, nkg2d:tä ja cd16:ta, ja käyttömenetelmiä | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2021058197A5 (enExample) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2017506217A5 (enExample) | ||
| JP2016528195A5 (enExample) | ||
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| JP2020508317A5 (enExample) | ||
| Becker et al. | Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP2016520082A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2019503349A5 (enExample) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| RU2016147206A (ru) | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака | |
| JP2015514113A (ja) | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 | |
| JP2018516966A5 (enExample) | ||
| FI3355919T3 (fi) | Yhdistelmähoito ihmisen kasvu- ja erilaistumistekijä 15:n (GDF-15) inhibiittoreita ja immuunitarkistuspiste-estäjiä käyttämällä | |
| Wang et al. | Targeting MSS colorectal cancer with immunotherapy: are we turning the corner? | |
| JP2012505922A5 (enExample) | ||
| JP2021511372A5 (enExample) | ||
| Mutlu et al. | Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer |